Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eplerenone for the Treatment of Central Serous Chorioretinopathy

Trial Profile

Eplerenone for the Treatment of Central Serous Chorioretinopathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Central serous chorioretinopathy
  • Focus Therapeutic Use
  • Acronyms ECSelsior
  • Most Recent Events

    • 09 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 19 Feb 2015 Planned End Date changed from 1 Oct 2014 to 1 May 2015 as per ClinicalTrials.gov record.
    • 19 Feb 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Mar 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top